ADHD Medication Abuse Risks Studied
Researchers compared safety reports to assess abuse and dependence risks for common ADHD treatments.
Updated on Sept. 22, 2026 in Substance Abuse
Live Poll
Do you trust that common ADHD medications have comparable risks for abuse and dependence?
A study published in General Psychiatry analyzed over 55,000 safety reports to compare abuse and dependence risks associated with ADHD medications. The findings reveal that lisdexamfetamine and methylphenidate carry comparable risks, while atomoxetine showed the lowest relative reporting.
Why it matters
Comparative real-world evidence regarding the abuse potential of ADHD treatments has historically been limited. These findings provide clarity on the relative risks associated with commonly prescribed medications, helping to inform safer clinical practice.
Researchers analyzed 55,219 reports, identifying 2,633 cases of abuse and dependence with 89.29% classified as serious. Reporting odds ratios indicated a 1.06 risk for lisdexamfetamine versus methylphenidate and a 0.36 risk for atomoxetine.
The players
General Psychiatry
This is a peer-reviewed academic journal that publishes research on mental health and psychiatric conditions.
VigiBase
This is the WHO's global database of individual case safety reports used to monitor the safety of pharmaceutical products.
The details
The analysis used the WHO global VigiBase database to calculate reporting odds ratios adjusted for factors including age, sex, and region. Notably, bupropion accounted for 47.13% of all identified cases, while individuals aged 15 to 25 represented over one-third of the reports.
Timeline
September 22, 2026: The study findings were published in the journal General Psychiatry.
Health Landscape
This study utilizes the WHO global VigiBase database to update established pharmacovigilance trends for ADHD medications. It marks a significant effort to synthesize global safety data, bridging the gap between varied national clinical observations.
These findings may influence how clinicians weigh the abuse potential of specific ADHD medications when initiating or adjusting patient treatment plans. Patients should discuss concerns regarding medication risks directly with their healthcare providers to ensure the safest therapeutic path.
The takeaway
Understanding the comparative risk profiles of psychiatric medications empowers patients to make more informed decisions about their treatment. Regular communication with medical professionals remains essential to monitor for adverse effects and ensure effective care.
Further reading
For more information on trends in medical research, visit Substance Abuse.
Source note: This article includes information reported by Psychiatry Advisor.
Live Poll
Do you trust that common ADHD medications have comparable risks for abuse and dependence?
